Author

Sean N. O’Byrne

University of DundeeORCID 0000-0002-1880-0239Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:virus· 1

Frequent Co-Authors

Colin Robinson· 2 shared Duncan E. ScottiD· 2 shared Ian Hugh GilbertiD· 2 shared Irene GeorgiouiD· 2 shared Sandra O’NeilliD· 2 shared Adrien DelpaliD· 1 shared Alex MatsudaiD· 1 shared Anna CzarnaiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

Colin Robinson

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Experience from an HTS campaign: Investigation of susceptibility and rescue of SARS-CoV-2 nsp3 protease assay from metal contamination

Irene Georgiou, Sandra O’Neill, Colin Robinson, Fraser Cunningham, Sean N. O’Byrne, David W. Gray, Ian Hugh Gilbert, Duncan E. Scott

The paper investigates false positives in SARS-CoV-2 nsp3 protease HTS assays caused by metal contamination and identifies copper and palladium as primary contaminants.

SLAS TECHNOLOGY · Mar 13, 2026Peer-reviewedBiochemistry

Crystallographic characterisation and development of bi-substrate inhibitors of coronavirus nsp14 methyltransferase

Irene Georgiou, Colin Robinson, Sean N. O’Byrne, Alex Matsuda, Przemysław Grygier, Craig D. L. Smith, Sandra O’Neill, Shamshad A. Ahmad, Suzanne Norval, John M. Post, G. J. Mirjam Groenewold, Nadya Urakova, Patrick Wanningen, Leanid Kresik, Jacek Plewka, , Ian Hugh Gilbert

The paper develops bi-substrate inhibitors of SARS-CoV-2 nsp14 methyltransferase using structure-guided design, achieving nanomolar potency but limited cellular antiviral activity.

RSC Medicinal Chemistry · Jan 1, 2026Peer-reviewedBiochemistry